Tumors have a variety of mechanisms to evade the immune system and so advancing our understanding of key effector immune cells in anti-tumor immunity will reveal novel targets for immunotherapy development. To that end, the immune cell-mediated cancer cell killing assay is a crucial resource to effectively assess the ability of a test article to modulate effector function against tumors.